These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 8485722)

  • 1. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy.
    Skitzki JJ; Muhitch JB; Evans SS
    Immunol Invest; 2007; 36(5-6):807-27. PubMed ID: 18161530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phorbol dibutyrate and ionomycin improve murine effector cell cytotoxicity.
    Hamby LS; Freeman JW; McGrath PC
    J Surg Res; 1993 Feb; 54(2):115-21. PubMed ID: 8479168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH
    APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R; Kamdar SJ; Duffy T; Edison L
    J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
    Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
    Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases.
    Takashima K; Fujiwara H; Inada S; Atsuji K; Araki Y; Kubota T; Yamagishi H
    Anticancer Res; 2006; 26(5A):3327-32. PubMed ID: 17094448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model.
    Lefor AT; Fabian DF
    J Surg Res; 1998 Feb; 75(1):49-53. PubMed ID: 9614856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
    Peyret C
    J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing fluorescent labeling of endothelial cells for tracking during long-term studies of autologous transplantation.
    Fox D; Kouris GJ; Blumofe KA; Heilizer TJ; Husak V; Greisler HP
    J Surg Res; 1999 Sep; 86(1):9-16. PubMed ID: 10452862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.
    Goldfarb RH; Koelemij R; Muirhead KA; Ohlsson-Wilhelm BM; Gray BD; Kuppen PJ; Basse PH; al-Atrash G; Kitson RP
    In Vivo; 2000; 14(1):101-4. PubMed ID: 10757065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.